NCT06056921View on ClinicalTrials.gov

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
SLE (Systemic Lupus)Sjogren's SyndromeSystemic SclerodermaDermatomyositisAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions
BIOLOGICAL

CD19 targeted CAR-T cells

A single infusion of CD19 CAR-T cells will be administered intravenously

Trial Locations (1)

Unknown

RECRUITING

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY